Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 7 studies | 37% ± 14% | |
epithelial cell | 6 studies | 27% ± 10% | |
transit amplifying cell | 3 studies | 23% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 28% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 52% | 5310.61 | 504 / 966 | 65% | 28.97 | 344 / 527 |
bladder | 43% | 802.76 | 9 / 21 | 54% | 23.84 | 274 / 504 |
skin | 71% | 6443.18 | 1287 / 1809 | 6% | 0.55 | 28 / 472 |
stomach | 0% | 0 | 0 / 359 | 60% | 25.34 | 171 / 286 |
prostate | 33% | 320.52 | 82 / 245 | 25% | 1.90 | 125 / 502 |
uterus | 1% | 7.11 | 2 / 170 | 38% | 11.79 | 176 / 459 |
esophagus | 0% | 3.59 | 7 / 1445 | 37% | 8.32 | 67 / 183 |
lung | 2% | 14.33 | 10 / 578 | 29% | 6.74 | 334 / 1155 |
tonsil | 0% | 0 | 0 / 0 | 27% | 4.87 | 12 / 45 |
pancreas | 0% | 0 | 0 / 328 | 21% | 8.14 | 38 / 178 |
ovary | 0% | 0 | 0 / 180 | 17% | 1.48 | 73 / 430 |
kidney | 15% | 84.75 | 13 / 89 | 1% | 0.05 | 5 / 901 |
liver | 0% | 0 | 0 / 226 | 5% | 1.69 | 22 / 406 |
adrenal gland | 0% | 0 | 0 / 258 | 3% | 0.20 | 6 / 230 |
breast | 0% | 12.69 | 1 / 459 | 2% | 0.49 | 21 / 1118 |
brain | 1% | 4.51 | 23 / 2642 | 0% | 0.01 | 1 / 705 |
thymus | 0% | 0 | 0 / 653 | 1% | 0.08 | 6 / 605 |
adipose | 0% | 3.97 | 3 / 1204 | 0% | 0 | 0 / 0 |
muscle | 0% | 1.27 | 1 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 1.96 | 1 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0070886 | Biological process | positive regulation of calcineurin-NFAT signaling cascade |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0015031 | Biological process | protein transport |
GO_0010922 | Biological process | positive regulation of phosphatase activity |
GO_0042307 | Biological process | positive regulation of protein import into nucleus |
GO_0032417 | Biological process | positive regulation of sodium:proton antiporter activity |
GO_0071277 | Biological process | cellular response to calcium ion |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CHP2 |
Protein name | Calcineurin B homologous protein 2 (Hepatocellular carcinoma-associated antigen 520) |
Synonyms | HCA520 |
Description | FUNCTION: Functions as an integral cofactor in cell pH regulation by controlling plasma membrane-type Na(+)/H(+) exchange activity. Binds to and activates SLC9A1/NHE1 in a serum-independent manner, thus increasing pH and protecting cells from serum deprivation-induced death. Also plays a role in the regulation of cell proliferation and tumor growth by increasing the phosphatase activity of PPP3CA in a calcium-dependent manner. Activator of the calcineurin/NFAT signaling pathway. Involved in the cytoplasmic translocation of the transcription factor NFATC3 to the nucleus. . |
Accessions | ENST00000300113.3 O43745 |